Home
Antipsychotic Use in Nursing Homes: Use With Caution

Antipsychotic Use in Nursing Homes: Use With Caution

Availability: In stock

Starts from: $197.00

Price as configured: $0.00

Event Information

Product format	Pre Recorded Event
Presenter	Dr. Christie Teigland, Ph.D.
Conference Date	Tuesday, February 10, 2009
Length	60 Minutes

Product Description

Are antipsychotics putting your residents with Alzheimer’s or dementia at risk?

If you don’t know all the risks that come along with using drugs off label with your residents who suffer from dementia or Alzheimer’s, you’re putting them at risk for stroke, seizures, or worse. While this practice can be effective, a growing body of research raises serious questions about the safety and efficacy of these drugs among the elderly. Let long term care expert Christie Teigland lay out all the pros and cons so you can best serve your patients while also protecting yourself.

Topics covered:

Reduce and eliminate unnecessary use of medication: How to identify good candidates for alternative behavioral intervention. Do your residents have legitimate psychoses or are they just aging typically? Here's how to tell the difference.
Getting at the underlying cause of your residents’ behavioral issues – and what happens if you don't identify and treat the root cause.
CMS’ Quality Measure for antipsychotic use: What it means for your facility’s off label use of drugs and F329-tag for unnecessary medications.
Review successful non-pharmacological approaches to managing and reducing problem behaviors in residents with dementia

Have additional questions? You have the floor with the speaker during an interactive Q&A.

Who should attend? Nurses; nurse practitioners; medical directors and physicians; nursing home interdisciplinary staff including psychologists, social workers, directors of nursing, quality improvement and risk management staff; pharmacists, and other clinicians involved in long term care and care of geriatric patients with dementia/Alzheimer Disease.

Your registration includes:

Flexible enrollment. Scheduling conflict? No problem. This session is also available on CD.
Expert answers to your tough questions during the interactive Q&A period.
Complimentary attendee package, including the speaker's complete presentation handouts. Keep this quick reference tool close by for future use.
One low price for all the staff you can stuff into a conference room.

Order Below Or Call 866-458-2965 Today

About the Speaker

Dr. Christie Teigland has specialized in long term care quality measurement research for the past 10 years. She has served as Principal Investigator for six large outcome studies, including a 4-year patient safety project funded by DHHS (AHRQ) that developed innovative predictive risk reports for falls and pressure ulcers. In 2005, DHHS (HRSA) awarded Dr. Teigland a large nurse education grant to develop online education modules to provide much needed training in the new ‘nursing informatics’ skills now essential to support complex clinical decision making, including how to use computerized patient data to improve resident outcomes and quality of care. She serves on several CMS expert panels including the MDS 3.0 Validation Panel evaluating changes to the Minimum Data Set, RAND panel to identify national patient safety indicators, and AHRQ panel to develop a national patient safety culture survey for long term care.

Dr. Teigland has been conducting research on antipsychotic use in the dementia population since 2004 when she was principal investigator for a study funded by Bristol-Myers Squibb. She has presented research findings at the American Psychiatric Association Annual Meeting (2007); 15th Annual Alzheimer’s Association Dementia Care Conference (2007); the Gerontological Society Association 60th Annual Scientific Meeting (2007), and the American Medical Director’s Association Annual Meeting (2008). She worked closely with Wall Street Journal Reporter Lucette Lagnado on a page 1 Wall Street Journal article published Dec. 4, 2007 “Prescription Abuse Seen in U.S. Nursing Homes” which quoted Dr. Teigland and incorporated data from her research. Dr. Teigland continues to work to evaluate the overuse of antipsychotics in the frail elderly nursing home population and is currently incorporating new quality measures into an informatics software tool that will provide better information about the degree of off-label use of these medications. The current research is funded by a grant from the national Alzheimer’s Association to develop quality of life measures for dementia and Alzheimer’s residents.